Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

NCT07413601 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer Metastatic

Interventions

DRUG: QL1706
DRUG: Cisplatin/ Carboplatin

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences